Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21342852 | 1.00 | TSHR (0.35) | TSHR | |
| SCHEMBL19234304 | 0.78 | — | — | |
| SCHEMBL20779243 | 0.74 | — | — | |
| SCHEMBL23023222 | 0.74 | — | — | |
| SCHEMBL25607212 | 0.74 | OPRM1 (0.42) | — | |
| SCHEMBL19283451 | 0.72 | — | — | |
| SCHEMBL21310463 | 0.70 | — | — | |
| SCHEMBL21148234 | 0.70 | TSHR (0.31) | TSHR | |
| SCHEMBL3998982 | 0.70 | DPP4 (0.31) | TSHR | |
| SCHEMBL4762655 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160376618-A1 | PROCESS FOR THE PREPARATION OF LISDEXAMFETAMINE AND RELATED DERIVATIVES | NORAMCO, LLC | 2016-12-29 | — | — | US | disclosed |
| US-20110263539-A1 | SHIP 1 MODULATOR COMPOUNDS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2011-10-27 | — | — | US | disclosed |
| US-20100323990-A1 | SHIP 1 MODULATOR PRODRUGS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2010-12-23 | — | — | US | disclosed |
| EP-0994108-B1 | PROCESS FOR PRODUCING 2-HYDROXYBENZAMIDE DERIVATIVES | ZERIA PHARM CO LTD (JP) | 2003-05-14 | — | — | EP | disclosed |
| US-6197970-B1 | REACTING WITH SECONDARY OR TERTIARY AMINE; DEBLOCKING, DEPROTECTING | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2001-03-06 | — | — | US | disclosed |
| EP-0994108-A1 | PROCESS FOR PRODUCING 2-HYDROXYBENZAMIDE DERIVATIVES | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2000-04-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100323990-A1 | SHIP 1 MODULATOR PRODRUGS | PPM1D, PPM1G, PPM1F | TSHR 4785/4885 |
| US-20110263539-A1 | SHIP 1 MODULATOR COMPOUNDS | PPM1F, PPM1D, PPP1R1B | TSHR 4329/4885 |
| US-20160376618-A1 | PROCESS FOR THE PREPARATION OF LISDEXAMFETAMINE AND RELATED DERIVATIVES | COMT, MGAM, GAA | TSHR 4189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.